The discovery of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), two key regulators of tumor cell growth, survival, metastasis, and angiogenesis, has led to the development of targeted therapies for colorectal cancer. Five targeted therapies are now approved for use in metastatic colorectal cancer (mCRC). These therapies modestly increase overall survival and progression-free survival in a heavily pretreated patient population.

**Key Points**
- Targeted therapy combined with chemotherapy is the standard of care in mCRC.
- EGFR inhibitors are beneficial in patients without KRAS mutations.
- VEGF inhibitors are beneficial in both KRAS mutated and wild-type patients.
- There are no head-to-head trials to identify the most effective or safest targeted therapy.
- The choice of targeted therapy in mCRC depends both on underlying mutations and previous therapy.
- Data support continuing antiangiogenic therapies beyond progression.

**Summary**

The discovery of key regulators in cancer cell growth has led to the development of targeted therapies in many cancers, including colorectal cancer. Five targeted therapies have been approved for use in metastatic colorectal cancer (mCRC) in combination with chemotherapy. Bevacizumab (Avastin®), ziv-afibercept (Zaltrap®), and regorafenib (Stivarga®) all target VEGF. Cetuximab (Erbitux®) and panitumumab (Vectibix®) are EGFR inhibitors.

Bevacizumab was the first VEGF inhibitor approved by the FDA. In the trials used to get this agent approved, the addition of bevacizumab to chemotherapy improved overall survival (OS) by 4.4 months compared with placebo in mCRC (20.3 months vs 15.6 months). There is still an improvement in survival even out to two years. There are data to support combining bevacizumab with single agent, doublet, or triplet chemotherapy. Thus, depending on the patient’s ability to tolerate chemotherapy, bevacizumab still adds survival benefit. There are also data demonstrating benefits of continuing bevacizumab even when the patient’s cancer has progressed.

Afibercept is a fusion protein of key domains from human VEGF receptors 1 and 2 with constant region (Fc) of human immunoglobulin G. It blocks all human VEGF-A isoforms, VEGF-B, and placental growth factor (PIGF). It binds VEGF-A and PIGF more tightly than native receptors. Because it has a different mechanism of action than bevacizumab, it hits more targets, which may be a possible benefit.

In the main study used for FDA approval, afiber-
cept was studied in combination with FOLFIRI (leucovorin, 5-fluorouracil (5-FU), and irinotecan (Camptosar). Addition of aflibercept increased OS by a median of 1.4 months. The hazard ratio (HR) was 0.82 so the people who received aflibercept had a 20 percent lower likelihood of death during the trial. It also increased progression-free survival by 2.2 months. It had similar effects whether patients were previously treated with bevacizumab or not (PFS difference 2.8 months, OS difference 0.8 months). Addition of this agent to standard chemotherapy does result in higher rates of certain adverse effects including hypertension, hemorrhage, proteinuria, and thromboembolic events, which are common adverse effects of VEGF inhibition. It has not been compared to bevacizumab in a trial.

Regorafenib is another new targeted therapy approved for mCRC. This is an oral multikinase inhibitor that targets multiple areas of tumor growth including VEGF (Exhibit 1). Regorafenib has been studied in combination with best supportive care in patients with mCRC who have progressed after standard therapy. The target population for this study were those with disease progression during or within three months after last administration of or intolerance to approved standard therapies, which had to include fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab. This was a very treatment-resistant study group. Addition of regorafenib improved OS by median 1.4 months and PFS by 0.2 months. The most common adverse effects of this agent are hand-foot skin reaction, rash, fatigue, hypertension, diarrhea, and voice change. Voice changes occur in about 30 percent of patients treated with VEGF inhibiting agents.

Certain genetic mutations have been identified in colorectal cancer. One of these is in the KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) gene. The protein product of the normal KRAS gene performs an essential function in normal tissue signaling, and the mutation of a KRAS gene is an essential step in the development of many cancers. Since KRAS can be used to predict outcomes of therapy, patients should be tested for KRAS mutations before treatment.

The story with KRAS mutation and response to therapy is different for the VEGF and EGFR inhibitors. KRAS mutation status does not have an impact on VEGF inhibitor efficacy but does for the EGFR inhibitors.

Cetuximab and panitumumab block the EGFR receptor. Around 40 percent of patients with colorectal cancer have KRAS mutations that bypass the EGFR receptor. In patients with these mutations, there is no benefit of adding an EGFR inhibi-
tor in those with KRAS mutation. Data as shown in Exhibit 2, EGFR inhibitors provide significant benefit in those with wild-type KRAS and no benefit in those with mutant KRAS. 

There are many different options for managing mCRC with combinations of chemotherapy and targeted agents and, in some cases, monotherapy with targeted agents. Exhibit 3 shows the treatment options for first-line and subsequent lines of therapy dependent on KRAS status.
Conclusion
Targeted therapy combined with chemotherapy has become the standard of care in mCRC. There are now several antiangiogenic therapies that target VEGF, but it is not known which is best because they have not been compared head-to-head. There are data to support continuing them beyond progression. EGFR inhibitors provide benefit for patients who do not have KRAS mutations. Importantly, KRAS mutation status does not impact antiangiogenic therapy outcome. There is a need for better biomarkers to decide on how best to select the targeted agents.

Bassel F. El-Rayes, MD is an Associate Professor of Hematology and Oncology at Winship Cancer Institute at Emory University in Atlanta, GA.

References